Experimental drug cilengitide tested with Chemo-Radiation for lung cancer
NCT ID NCT01118676
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested the drug cilengitide given continuously along with standard chemotherapy and radiation in 14 patients with locally advanced non-small cell lung cancer. The main goal was to find the highest safe dose of cilengitide when used this way. Researchers also looked at how well the tumors responded and how long patients lived.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cilengitide
What this could lead to
If successful, this could help determine a safe dose of cilengitide combined with standard chemoradiation for advanced lung cancer.
What could go wrong
This is a very early, small Phase 1 trial with only 14 patients, so it cannot prove effectiveness. The main goal is safety, not treatment benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED NON SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Toulouse Larrey
Toulouse, 31000, France
-
Institut Claudius Regaud
Toulouse, 31000, France